Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908467 | 0.85 | MDM2 (0.31) | MDM2P2RX7 | |
| SCHEMBL20672146 | 0.73 | PIK3CD (0.33) | PIK3CD | |
| SCHEMBL12021225 | 0.72 | — | — | |
| SCHEMBL12213138 | 0.72 | — | — | |
| SCHEMBL12021331 | 0.72 | — | — | |
| SCHEMBL10160264 | 0.72 | — | — | |
| SCHEMBL10049353 | 0.71 | PIK3CD (0.56) | PIK3CDAR | |
| SCHEMBL9926817 | 0.71 | PIK3CD (0.56) | PIK3CDAR | |
| SCHEMBL9926814 | 0.71 | PIK3CD (0.56) | PIK3CDAR | |
| SCHEMBL9980265 | 0.68 | SRD5A1 (0.39) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879022-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | PFIZER INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-5001113-A | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO., INC. (US) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160347760-A1 | Bicyclic-Fused Heteroaryl or Aryl Compounds | UGT2B7, CYP3A43, CYP3A4 | PIK3CD 2776/4885AR 283/4885MDM2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.